Results 141 to 150 of about 1,708,559 (358)
This study explores salivary RNA for breast cancer (BC) diagnosis, prognosis, and follow‐up. High‐throughput RNA sequencing identified distinct salivary RNA signatures, including novel transcripts, that differentiate BC from healthy controls, characterize histological and molecular subtypes, and indicate lymph node involvement.
Nicholas Rajan +9 more
wiley +1 more source
On a peculiar arrangement of Blood‐vessels in the Air‐bladder of Fishes, with some remarks on the evidence which they afford of the true function of that organ [PDF]
John Quekett
openalex +1 more source
On the ontogeny of the chondral skull in Characidae, with a discussion on the chondrocranial base and the visceral chondrocranium in fishes [PDF]
Gunnar Bertmar
openalex +1 more source
Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts +8 more
wiley +1 more source
The quality of crustacean aquatic products is affected by feed. Cholesterol (CHO), an essential element for crustacean growth, has been widely supplemented in diet, but its food quality regulation remains unclear.
Tingting Zhu +6 more
doaj +1 more source
Note on Bucklandium diluvii, Köuig, a Siluroid Fish from the London Clay of Sheppey
Arthur Smith Woodward
openalex +2 more sources
A‐to‐I editing of miRNAs, particularly miR‐200b‐3p, contributes to HGSOC progression by enhancing cancer cell proliferation, migration and 3D growth. The edited form is linked to poorer patient survival and the identification of novel molecular targets.
Magdalena Niemira +14 more
wiley +1 more source
X. On the development of the teeth of fishes (Elasmobranchii and Teleostei) [PDF]
Charles S. Tomes, Charles S. Tomes
openalex +1 more source
This real‐world study of ROS1+ NSCLC highlights fusion diversity, treatment outcomes with crizotinib and lorlatinib, and in vitro experiments with resistance mechanisms. G2032R drives strong resistance to ROS1‐targeted TKIs, especially lorlatinib. Fusion partner location does not affect overall survival to crizotinib or lorlatinib. Findings support the
Fenneke Zwierenga +8 more
wiley +1 more source

